Primary leptomeningeal histiocytic sarcoma in a patient with a good outcome: a case report and review of the literature

Elisabeth Pérez-Ruiz1, Maite Delgado1, Andrés Sanz2, Ana Maria Serradilla Gil3 and Antonio Rueda Domínguez1

Abstract

Introduction: Histiocytic sarcoma is a rare neoplasm with few cases reported in the literature of which some were diagnosed in animals. This neoplasm arises from abnormal reticuloendothelial system cell proliferation of histiocytes and has an aggressive behavior especially if located in the central nervous system. We present the first case of a patient with histiocytic sarcoma that involved the meninges and had a good course after multidisciplinary treatment.

Case presentation: Our patient was a 41-year-old Caucasian woman with no previous history of disease who started with systemic symptoms such as headache and chills. Magnetic resonance imaging with gadolinium contrast of the brain suggested a mass 1.5×2cm in diameter in the temporal lobe with a non-uniform vasogenic edema. This lesion was implanted in the meninges and surgery was the first treatment. The histological findings revealed a histiocytic sarcoma. The patient received concomitant chemoradiotherapy after surgery with good tolerance and currently lives without disease.

Conclusion: Although histiocytic sarcomas in the brain present an unusual location and have a poorer prognosis, we have identified the first primary leptomeningeal histiocytic sarcoma with a disease-free survival greater than 3 years following multidisciplinary treatment with surgery and chemotherapy and radiotherapy.

Keywords: Chemotherapy, Histiocytic sarcoma, Leptomeningeal sarcomas, Multidisciplinary treatment, Radiotherapy

Introduction

Histiocytic sarcoma (HS) is a rare neoplasm showing evidence of histiocytic differentiation. It often appears in the skin, lymph nodes, and intestinal tract but central nervous system (CNS) involvement is rare. The standard treatment for these sarcomas is surgery. The best option for treating these tumors is unclear and affected patients have a poor prognosis despite treatment.

Case presentation

In June 2009, a 41-year-old Caucasian woman with no previous history of illness went to the Emergency Room with systemic symptoms, including headache, generalized weakness, and chills. The physical examination showed nothing remarkable. The workup included a computed tomography (CT) brain scan without contrast that showed nothing unusual. The patient received empirical treatment for a diagnosis of a suspected viral infection. A week later, she presented with dysphasia and deviation of the right corner of her mouth. Magnetic resonance imaging (MRI) with gadolinium contrast of the brain suggested a mass 1.5×2cm in diameter in the temporal lobe with a non-uniform vasogenic edema. This lesion was implanted in the meninges and indicated possible meningioma (Figure 1). There was no evidence of malignancy on chest, abdominal or pelvic CT. In July, left frontal craniotomy surgery was performed. It showed a meningeal lesion in the dura mater extending to nearby tissue. The lesion was excised in its entirety (Figure 2A). The histological finding described a lesion in the meninges with a diameter of 3×2cm. The histological findings also revealed a diffuse non-cohesive proliferation of neoplastic cells that looked like a histiocyte. The cells were variable in size, with large and abundant foamy eosinophilic cytoplasm. The
cytoplasm presented numerous neutrophils and phagocytosis by tumor cells. The nuclei were irregular and large with mono- or multi-nucleation displaying a vacuole appearance with granular chromatin. It frequently presented prominent eosinophilic nucleoli. There was a lymphocyte and neutrophil inflammatory background (Figure 2B). The entire lesion was neoplastic. The pathologist suggested a lymphoma but an immunohistochemistry study was done the results of which showed positive expression of CD68 (Figure 2C), CD163 and lysozyme consistent with histiocytic lineage and weak expression of S100. The cells, however, presented negative expression of cytokeratin, B or T cells, and myeloid markers, including anaplastic lymphoma kinase 1 (ALK-1), CD3, CD4, CD8, CD20, CD21, CD23, CD30, CD1a, Bcl2, Bcl6, CD15, CD31 and CD10. The polymerase chain reaction study did not show clonal B or T cells. After these results, the pathologist diagnosed a HS. We presented the case in the

Figure 1 Magnetic resonance imaging demonstrating meningeal involvement and possible neoplastic disease. From left to right: Axial T1 image, coronal T1 image, and axial T2 image.

Figure 2 Histological findings. A. Laminar fragment corresponding to dura mater (right) on which arises the tumor. B. Diffuse non-cohesive proliferation of neoplastic cells that look like a histiocyte. The cells are variable in size, with irregular nuclei and a strikingly large central nucleus. There is a lymphocyte and neutrophil inflammatory background showing numerous neutrophils and phagocytosis by tumor cells. C. Positive expression of CD68 in tumor cells.
multidisciplinary meeting and we decided on adjuvant treatment with chemo radiotherapy: temozolomide (120mg daily) concomitant with 1.8Gy of radiotherapy 5 days a week. The radiotherapy was intensity-modulated radiation therapy guided by imaging: planning target volume (PTV) 1 received 45Gy, PTV2 received 54Gy and PTV3 61.2Gy. The patient remains disease free after 42 months.

Discussion
HS also formerly known as “true” histiocytic lymphoma is a rare neoplasm showing evidence of histiocytic differentiation. It often appears in the skin, lymph nodes, and intestinal tract [1]. Although CNS involvement is rare, there are a few cases reported in the literature [1-5] and other cases in the literature addressing the brain is MRI [7], which have improved immunohistochemistry findings, allowing for differentiation between HS and B or T cells and non-Hodgkin lymphomas. These diseases have a prognosis and treatment different from sarcomas.

HS is composed of mononuclear tumor cells with large cytoplasmic vacuoles. Some cells present with phagocytosis phenomena. The diagnosis is based on immunohistochemistry markers of histiocytic cells such as positive CD68, lysozyme, α1-antitrypsin and CD163, which is regarded as a specific HS marker [11]. However, advances in molecular and biological markers have improved immunohistochemistry findings, allowing for differentiation between HS and B or T cells and non-Hodgkin lymphomas. These diseases have a prognosis and treatment different from sarcomas.

HS has often been classified as being similar to diseases such as malignant histiocytosis, histiocytic lymphoma, and reticular sarcoma, based on morphological criteria [10]. However, advances in molecular and biological markers have improved immunohistochemistry findings, allowing for differentiation between HS and B or T cells and non-Hodgkin lymphomas. These diseases have a prognosis and treatment different from sarcomas.

The standard treatment for these sarcomas is surgery. The best option for treating these tumors is unclear. Furthermore, when the tumor is located in the CNS therapeutic options are reduced. Brain sarcomas have an aggressive course with an overall survival rate of around 4 to 5 months, regardless of treatment. There are no studies where the benefit of radiotherapy or chemotherapy for HS has been established.

In our case, the patient received concomitant chemo radiotherapy after surgery. We decided to administer temozolomide with the radiotherapy because the patient was young and she presented with a sarcoma affecting the CNS. It is also known that this type of chemotherapy crosses the blood–brain barrier and it has shown benefit over radiotherapy alone in other aggressive tumors [13]. She had a good tolerance and currently lives without disease (disease-free interval of 42 months). The cases reported before were treated with different schedules of chemotherapy by the vein or with intrathecal treatment but none received concomitant radiotherapy. All the cases had an aggressive course except one case that relapsed after 3 years [1]. In the literature, some cases of extranodal HS treated with surgery and some type of chemotherapy or radiotherapy had a good outcome. These reported patients lived varying months after treatment [14]. Recently, a radiotherapy-induced HS has been treated with radiation alone and the patient remained free of recurrent disease after 1.5 years [15]. Radiation alone could be beneficial but we do not know whether radiation-induced HS differ in their biological behavior.

Conclusion
In conclusion, HS is a rare neoplasm with a diagnosis based on immunohistochemistry and biological findings. Although HS in the brain present an unusual location and have a poorer prognosis, we have identified the first primary leptomeningeal HS with a disease-free survival greater than 3 years following treatment with surgery and chemotherapy and radiotherapy.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
EPR and AR analyzed and interpreted the patient data regarding the sarcoma histiocytic disease and the treatment. AS performed the histological examination of the brain, and was a major contributor in writing the manuscript. MD and AMS treated the patient. All authors read and approved the final manuscript.

Author details
1 Division of Medical Oncology, REDISSEC, Hospital Costa del Sol, Autovía A-7, Km 187, C.P. 29603, Marbella, Spain. 2 Pathology Department, Hospital Universitario Carlos Haya, Málaga, Spain. 3 Division of Radiotherapy Oncology, Clinic Croasa, Málaga, Spain.
References
1. Cheuk W, Walford N, Lou J, Lee AK, Fung CF, Au KH, Mak LS, Chan JK. Primary histiocytic lymphoma of the central nervous system. *Am J Surg Pathol* 2001, 25:1372–1379.
2. Cao M, Eshoa C, Schultz C, Black J, Zu Y, Chang CC. Primary central nervous system histiocytic sarcoma with relapse to mediastinum. *Arch Pathol Lab Med* 2007, 131:301–305.
3. Sun W, Nordberg M, Fowler M. Histiocytic sarcoma involving the central nervous system. *Am J Surg Pathol* 2003, 27:258–265.
4. Colovic N, Jurisic Y, Colovic M. Malignant histiocytosis with central nervous system involvement and hepatic mucinous cystadenoma in a single patient with review of the literature. *J BUON* 2007, 12:539–542.
5. Torres CF, Korones D, Powers J, Vadasz AG. Primary leptomeningeal histiocytic lymphoma in a young child. *Med and Pediat Oncology* 1996, 27:547–550.
6. Molenaar FM, Breed EJ, Flach I, McDandlish IA, Pocknell AM, Strike T, Routh A, Taema M, Summers BA. Brain tumours in two Bactrian camels: a histiocytic sarcoma and a meningioma. * Vet Rec* 2009, 164:684–688.
7. Tamura S, Tamura Y, Nakamoto Y, Ozawa T, Uchida K. MR imaging of histiocytic sarcoma of the canine brain. *Vet Radiol Ultrasound* 2009, 50:78–81.
8. Uchida K, Morozumi M, Yarnaguchi R, And TS. Diffuse leptomeningeal malignant histiocytosis in the brain and spinal cord of a Tibetan Terrier. *Vet Pathol* 2001, 38:219–222.
9. Ide T, Uchida K, Tamura S, Nakayama H. Histiocytic sarcoma in the brain of a cat. *J Vet Med Sci* 2010, 72:99–102.
10. Hirose S, Shimada S, Takebe Y, Tokunri Y, Kawano H, Kubota T. Recurrent malignant histiocytosis with cerebrospinal involvement. *Neural Med Chir* 1994, 34:233–236.
11. Vos JA, Abdoudanzo SL, Durekman C, Andriko JW, Miettinen M, Aguilera NS. Histiocytic sarcoma: a study of five cases including the histocyte marker CD163. *Mod Pathol* 2005, 18:693–794.
12. Pilen SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, Favera RD, Deloof G, De Wolf-Peeters C, Falini B, Gascoyne RD, Gaulard P, Gatter KC, Isaacson PG, Jaffe ES, Kluin P, Laitman DJ, McNeil MJ, Muller-Hermelink HK, Neri MA, Ralfkiaer E, Stein H, Su JI, Warnke RA, Weiss LM. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. *Histopathology* 2002, 41:1–29.
13. Stupp R, Mason WP, Van den Bent M, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Cuningham J, Janzer RC, Ludwig SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005, 352:987–996.
14. Horneck J, Jaffe ES, Fletcher C: Extranodal histiocytic sarcoma. Clinicopathological analysis of 14 cases of a rare epithelioid malignancy. *Am J Surg Pathol* 2004, 28:1133.
15. Wu W, Sayit T, Vinters HV, Pope W, Misdraji L, Said J. Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: case report and literature review. *Hum Pathol* 2013, 26. Epub ahead of print.